Michael Kelly-Sell, MD
MOHS-Micrographic Surgery · Plano, TXNPI 1790042620
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,579 of the $2,210 with a category attached, or 71.5%. 14 manufacturers reported payments, led by Angiodynamics, Inc. at 46.5% of the total. Reporting peaked in 2019 at $1,659 and has fallen 88.9% since, to $184 in 2025.
Across 27 payments — averaging $81.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Angiodynamics, Inc.$1K
- AbbVie$556
- Genentech USA, Inc.$157
- Kerecis Limited$127
- Lilly USA, LLC$84
- Galderma Laboratories, L.p.$64
- plus $192 from 8 others
What the payments were for
- Travel & lodging$63129%
- Food & beverage$1,57971%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Angiodynamics, Inc. | 2 | $1,028 |
| AbbVie(2 entities) | 6 | $556 |
| Genentech USA, Inc. | 3 | $157 |
| Kerecis Limited | 3 | $127 |
| Lilly USA, LLC | 2 | $84 |
| Galderma Laboratories, L.p. | 1 | $64 |
| Mimedx Group, Inc. | 3 | $49 |
| Medtronic | 1 | $23 |
| Incyte Corporation | 1 | $23 |
| Organogenesis Inc. | 1 | $23 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Johnson & Johnson | 1 | $20 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,210 in reported general payments places this provider in the 55th percentile of 109 mohs-micrographic surgery providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Doxycycline Hyclate | 213 | $1,202 |
| Mupirocin | 14 | $106 |
Paid to pharmacies, not to this prescriber.
Other mohs-micrographic surgery in Plano
- Aatman ShahPlano$5K
- Gunjan ModiPlano$2K
- Michael WellsPlano$2K
- Eric HollabaughPlano$1K
- Aaron FarbergRockwall$1.5M
- Suneel ChilukuriBellaire$288K
- Ryan O QuinnSan Antonio$167K
- Paul FriedmanHouston$131K
- Brent SpencerFrisco$45K
- Julie CroleyThe Woodlands$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.